1

2
Bai Hao, Bailey Simon, Bhumralkar Dilip Ramakant, Bi Feng, Guo Fengli, He Mingying, Humphries Paul Stuart, Ling Anthony Lai, Lou Jihong, Nukui Seiji, Zhou Ru: Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases. Pfizer Products, Bai Hao, Bailey Simon, Bhumralkar Dilip Ramakant, Bi Feng, Guo Fengli, He Mingying, Humphries Paul Stuart, Ling Anthony Lai, Lou Jihong, Nukui Seiji, Zhou Ru, FULLER Grover F Jr, November 1, 2007: WO/2007/122482 (41 worldwide citation)

The present invention relates to a compound of formula (I): (I); or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: B(i); and B(ii); Ring A, ring B, ring C, R1, R1a, R2, R3, ...


3

4
Chu Shao Song, Alegria Larry Andrew, Bender Steven Lee, Benedict Suzanne Pritchett, Borchardt Allen J, Kania Robert Steven, Nambu Mitchell David, Tempczyk Russell Anna Maria, Sarshar Sepehr, Bhumralkar Dilip, Peng Zhengwei, Yang Yi Michelle: Diaminothiazoles and their use for inhibiting protein kinases. Agouron Pharmaceuticals, PINO Mark J, December 14, 2000: WO/2000/075120 (4 worldwide citation)

Diaminothiazole compounds of formula (I) that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell ...


5
Teng Min, Truesdale Larry Kenneth, Bhumralkar Dilip, Kiel Dan, Johnson Michael D, Thomas Christine, Jorgensen Anker Steen, Madsen Peter, Olesen Preben Houlberg, Knudsen Liselotte Bjerre, Petterson Ingrid Vivika, Cornelis de Jong Johannes, Behrens Carsten, Kodra Janos Tibor, Lau Jesper: Non-peptide glp-1 agonists. Novo Nordisk, Agouron Pharma, October 24, 2001: EP1147094-A1 (2 worldwide citation)

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is benef ...


6

7
Bender Steven Lee, Bhumralkar Dilip, Collins Michael Raymond, Cripps Stephan James, Deal Judith Gail, Nambu Mitchell David, Palmer Cynthia Louise, Peng Zhengwei, Varney Michael David, Jia Lei: Amide compounds for inhibiting protein kinases. Agouron Pharmaceuticals, GADIANO Christina, July 26, 2001: WO/2001/053274 (2 worldwide citation)

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invent ...


8

9
Cui Jingjong Jean, Zhang Jennifer, Hanau Cathleen Elizabeth, Bhumralkar Dilip, Botrous Iriny, Chu Ji Yu, Funk Lee A, Harris Jr G Davis, Jia Lei, Johnson Joanne, Kolodziej Stephen A, Kung Pei Pei, Li Xiaoyuan Sharon, Lin Jason Qishen, Meng Jerry Jialun, Nambu Mitchell David, Nelson Christopher G, Pairish Mason Alan, Shen Hong, Tran Dube Michelle: Aminoheteroaryl compounds as protein kinase inhibitors. Sugen, December 14, 2005: EP1603570-A2

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.


10